Kuhajda F P, Abeloff M D, Eggleston J C
Hum Pathol. 1985 Mar;16(3):228-35. doi: 10.1016/s0046-8177(85)80007-1.
The primary tumors and metastases from 30 patients with stage II breast carcinoma treated with low- or standard-dose combination chemotherapy (cyclophosphamide, methotrexate, 5-fluorouracil) were studied by the immunoperoxidase technique for pregnancy-associated plasma protein A (PAPP-A), pregnancy-specific beta-1-glycoprotein (SP-1), and placental protein five (PP-5). In addition to immunostaining, 25 traditional clinicopathologic features were assessed with respect to early (at less than two years) recurrence. Of the 11 patients with early recurrences, nine (82 per cent) were PAPP-A-positive, while 16 of the 19 patients without early recurrences (84 per cent) were PAPP-A-negative (P less than 0.0005). None of the other clinicopathologic features correlated with early recurrence. Immunostaining for PAPP-A is thus a clinically significant predictor of early recurrence in patients with stage II breast carcinoma.
采用免疫过氧化物酶技术，对30例接受低剂量或标准剂量联合化疗（环磷酰胺、甲氨蝶呤、5-氟尿嘧啶）治疗的II期乳腺癌患者的原发肿瘤和转移灶进行妊娠相关血浆蛋白A（PAPP-A）、妊娠特异性β1糖蛋白（SP-1）和胎盘蛋白5（PP-5）检测。除免疫染色外，还评估了25项传统临床病理特征与早期（两年内）复发的关系。在11例早期复发患者中，9例（82%）PAPP-A呈阳性，而19例无早期复发患者中有16例（84%）PAPP-A呈阴性（P<0.0005）。其他临床病理特征均与早期复发无关。因此，PAPP-A免疫染色是II期乳腺癌患者早期复发的一个具有临床意义的预测指标。
